-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

FUJIFILM Cellular Dynamics Announced Thursday, A License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies

Benzinga · 01/06/2023 05:11
FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics' iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases. Under the agreement, Novo Nordisk will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for clinical and commercial manufacture and commercialization of iPSC-derived cell therapies. Terms of the agreement were not disclosed.